SCHEMBL3522744

SCHEMBL3522744

COC(=O)CCCC#Cc1cc(Cl)ccc1NS(=O)(=O)c1cc(OC)ccc1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
NPSR1 Q6W5P4 2/20 0.48
TP53 P04637 2/20 0.47
WDR5 P61964 4/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPT P10636 3/20 0.46
HTT P42858 2/20 0.46
GAA P10253 2/20 0.46
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.46
PKM P14618 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
CASP1 P29466 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TSHR P16473 2/20 0.45
NPC1 O15118 1/20 0.45
LMNA P02545 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3524449 0.94 ALDH1A1 (0.53) ALDH1A1NPSR1TP53WDR5MEN1
SCHEMBL3525068 0.87 LMNA (0.51) ALDH1A1TP53MEN1KMT2AMAPT
SCHEMBL3527759 0.84 SLC16A3 (0.48) ALDH1A1NPSR1MEN1KMT2AMAPT
SCHEMBL3523112 0.82 CCR9 (0.42) TP53KMT2AMAPTHTTLMNA
SCHEMBL3526360 0.81 PTGES2 (0.48) MAPT
SCHEMBL3523974 0.81 ALDH1A1 (0.48) ALDH1A1NPSR1TP53WDR5MEN1
SCHEMBL3527490 0.81 LMNA (0.53) ALDH1A1TP53MEN1KMT2AMAPT
SCHEMBL3523363 0.80 SLC16A3 (0.43) ALDH1A1MEN1KMT2ATSHR
SCHEMBL4878167 0.80 MAPT (0.53) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL3528825 0.79 ALDH1A1 (0.56) ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP ALDH1A1 1607/4885NPSR1 669/4885TP53 3755/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG ALDH1A1 1453/4885NPSR1 239/4885TP53 2497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.